S
Sibylla Biotech
Biotech & Life Sciences · Bresso, Italy · Founded 2017
Facing the complexity of drug discovery with the power of an innovative approach for meeting unmet medical needs MoreLess
Sibylla Biotech is a preclinical stage company that focuses on developing innovative small molecule degraders to address unmet medical needs. Utilizing a novel Mechanism of Action called Protein Inactivation by Folding Intermediates (PPI FIT), Sibylla identifies and develops small molecules that target proteins involved in various diseases. The company operates in the biopharmaceutical market and collaborates with academic institutions like the Italian National Institute of Nuclear Physics, the University of Trento, and the University of Perugia. Sibylla's business model revolves around drug discovery and development, leveraging advanced computational simulations and AI platforms to accelerate the identification of potential therapeutics. Revenue is generated through partnerships, grants, and potential future licensing deals. The company serves pharmaceutical companies and research institutions looking for novel therapeutic solutions.
Keywords: small molecule degraders, PPI FIT, drug discovery, preclinical stage, therapeutic areas, protein regulation, computational simulations, AI platform, biopharmaceutical, unmet medical needs.
Company overview
Sibylla Biotech company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- Bresso, Italy
- Employees
- 43
- Open positions
- None listed
- Dealroom signal
- 78.9
Valuation & funding
Sibylla Biotech funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2022 | $25M | $101M | CDP Venture Capital · Seroba Life Sciences · 3B Future Health Fund · Vertis | ↗ |
| SPINOUT✓Other financing | Jan 2017 | $0 | — | University of Trento · Italian Institute for Nuclear Physics · University of Perugia | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Sibylla Biotech website traffic
Latest recorded traffic for Sibylla Biotech is 1K monthly website visits, up 78.6% over the last three months. Sibylla Biotech's team grew 13.2% over the past year.
Comparisons
Sibylla Biotech compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Sibylla Biotech's talent
Source: Dealroom Talent Intelligence.
Investors
12 investors on Sibylla Biotech's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Sibylla Biotech has talent and traffic
team presence
In the news
Latest news about Sibylla Biotech
Recent press, funding announcements, and product moves mentioning Sibylla Biotech — open to read from the original sources.
Market sentiment
What the market is saying about Sibylla Biotech
An AI-synthesized read of the highest-engagement posts about Sibylla Biotech on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sibylla Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.